Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04134936 · ClinicalTrials.gov registry record · Phase 1
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
A Phase 1 study, sponsored by MorphoSys.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT04134936 is a Phase 1 study that has completed, run by MorphoSys. The registered enrollment target is 66 participants.
The verdict
NCT04134936, a Phase 1 study, has completed, sponsored by MorphoSys.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is an open-label, randomized, multicentre study to evaluate safety and preliminary efficacy of the human anti-CD19 antibody Tafasitamab in addition to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) or Tafasitamab and Lenalidomide in addition to R-CHOP in adult patients with newly diagnosed, previously untreated Diffuse Large B-cell Lymphoma (DLBCL).
Interventions
- DRUG Tafasitamab
- DRUG Tafasitamab plus lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2019-12-11 |
| Est. Completion | 2022-08-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04134936
The ClinicalTrials.gov registry entry for NCT04134936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MorphoSys, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tafasitamab is the first listed.
NCT04134936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04134936 about?
NCT04134936 is a clinical study titled "Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL". This is an open-label, randomized, multicentre study to evaluate safety and preliminary efficacy of the human anti-CD19 antibody Tafasitamab in addition to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) or Tafasitamab and Lenalidomide in addition to R-CHOP in adult patien...
What is the current status of trial NCT04134936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2019-12-11. Estimated completion is 2022-08-10.
What interventions are being tested in trial NCT04134936?
The interventions under investigation include: Tafasitamab (DRUG), Tafasitamab plus lenalidomide (DRUG).
Who is sponsoring clinical trial NCT04134936?
This trial is sponsored by MorphoSys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.